Xaira Therapeutics, Inc.

Pioneering AI-driven breakthroughs in drug discovery and development for faster, more effective therapies

Xaira Therapeutics is a Seattle and San Francisco Bay Area-based biotechnology company that leverages artificial intelligence to revolutionize the drug discovery and development process. Co-founded by Dr. David Baker, with initial funding led by ARCH Venture Partners and Foresite Labs, Xaira Therapeutics embodies a convergence of cutting-edge AI research, extensive biological data generation, and comprehensive therapeutic product development. The company's platform utilizes machine learning to better understand biological mechanisms, fostering the development of more effective therapies. By incorporating AI across all facets of drug development—from molecular design to clinical trials—Xaira aims to accelerate the creation of transformative medicines, targeting previously challenging biological issues. With over $1 billion in committed capital and a leadership team featuring renowned experts like Dr. Marc Tessier-Lavigne, Xaira is positioned to lead significant advancements in medical biotechnology. The firm is set to redefine therapeutic development, promising a future where AI-driven discoveries rapidly transition into lifesaving treatments.